邓普顿新兴市场基金 EMF 深 沪
等待开盘 10-21 09:30:00 美东时间
17.00
+0.200
+1.19%
华盛通- 最 高17.0033
- 今 开16.86
- 成交量 1.19万股
- 最 低 16.86
- 昨 收 16.80
- 总市值 2.56亿
- 52周最高 17.29
- 市盈率 静 9.10
- 换手率 0.08%
- 52周最低 10.70
- 委 比 0.00%
- 总股本 1503.07万
- 历史最高 17.29
- 量 比 0.26
- 振 幅 0.85%
- 历史最低 4.6056
- 每 手 1
- 风险率 1.72%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多2025年上海市车载吸尘器产品质量监督抽查结果公布
中国质量新闻网讯 据上海市市场监督管理局网站消息，近期，上海市市场监督管理局对本市生产、销售的车载吸尘器产品质量进行了监督抽查。本次抽查了30批次产品。经检验...
10-13 16:52
Johnson & Johnson's TREMFYA Shows 48-Week Remission Results In Ulcerative Colitis With First Fully Subcutaneous IL-23 Inhibitor
Patients treated with subcutaneous TREMFYA® achieved clinically meaningful results in both clinical remission (36.7%) and endoscopic remission (25.9%) at Week 48 in the Phase 3 ASTRO studyClinical and endoscopic
10-07 20:10
老黄9亿美元再投AI Infra，这次直接打包带走CEO和核心技术
不圆 发自 凹非寺 量子位 | 公众号 QbitAI 刚入股了“老对手”英特尔，老黄又豪掷9亿美刀，拿下一家AI Infra公司……的CEO和技术授权。 最新消...
09-21 14:34
Johnson & Johnson Receives FDA Approval For Subcutaneous Induction Regimen Of TREMFYA; TREMFYA Offers The Flexibility Of Self-Administration From The Start Of Treatment, Building On The Prior Approval Of Subcutaneous Induction In Crohn's Disease;
HORSHAM, Pa., Sept. 19, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) today announced that the U.S. Food and Drug Administration (FDA) has approved a subcutaneous (SC) induction regimen of TREMFYA®
09-20 05:32
Templeton Emerging Markets Fund Inc. declares $0.22 dividend
Templeton Emerging Markets Fund Inc. (NYSE:EMF) declares $0.22/share quarterly dividend, in line with previous. Forward yield 5.66% Payable Sept. 30; for shareholders of record Sept. 18; ex-div Sept. ...
09-09 21:09
英伟达投资的Enfabrica发布旨在降低内存成本的系统
总部位于硅谷的芯片初创公司 Enfabrica 致力于解决人工智能数据中心的瓶颈问题，该公司周二发布了一套芯片与软件系统，旨在控制这些数据中心中内存芯片的成...
07-29 21:14
Johnson & Johnson Submits sBLA To FDA For TREMFYA Label Expansion In Psoriatic Arthritis
Submission is supported by 24-week results from the Phase 3b APEX study in adults with active psoriatic arthritis treated with TREMFYA®, the only dual-acting IL-23 inhibitor HORSHAM, Pa., July 29,
07-29 20:11
Franklin Templeton announces Q2 share repurchase activity for select funds
Investment management organization Franklin Resources (NYSE:BEN), better known as Franklin Templeton, announced on Monday the second-quarter share repurchase activity for select funds. Putnam Managed ...
07-21 20:43
Johnson & Johnson Q2 Preview: Focus on tariff threat, MedTech softness
Johnson & Johnson (NYSE:JNJ) is set to kick off the second quarter pharma earnings on Wednesday, with investors focusing on the drugmaker’s guidance amid U.S. President Donald Trump’s ongoing threats ...
07-16 02:19
